Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to pinpoint how Genpact recognizes contract revenue or which segment drives its digital transformation growth? With subsidiaries across 25+ countries, Genpact’s disclosures can stretch beyond 250 pages, and the footnotes on long-term service contracts, Data-Tech-AI investments, and client concentration often hide deep inside. If you’re searching for “Genpact SEC filings explained simply,” this page delivers. Stock Titan surfaces the answers in seconds.
Our AI-powered summaries translate every Genpact SEC document—from an 8-K on a new outsourcing deal to the annual report 10-K—into plain language. Whether you search “Genpact insider trading Form 4 transactions” or “understanding Genpact SEC documents with AI,” you’ll find real-time insights, keyword tagging, and cross-linking that make navigation effortless.
Need the latest numbers? The “Genpact quarterly earnings report 10-Q filing” section highlights revenue by vertical, margin movement, and cash-flow trends, while our dashboards compare quarter-over-quarter performance. For governance questions, the proxy statement area breaks down Genpact executive compensation, option awards, and CEO pay ratio. Monitoring management moves? Get instant alerts on “Genpact Form 4 insider transactions real-time” so you never miss a buyback or stock grant.
Every filing type is covered and explained:
- 10-K annual report—strategy shifts, customer concentration, risk factors simplified (“Genpact annual report 10-K simplified”).
- 10-Q quarterly update—data tables annotated, segment commentary summarized (“Genpact earnings report filing analysis”).
- 8-K material events—contract wins or leadership changes distilled (“Genpact 8-K material events explained”).
- Form 4—executive stock moves tracked live (“Genpact executive stock transactions Form 4”).
- DEF 14A proxy—board structure and incentive plans clarified (“Genpact proxy statement executive compensation”).
Stop scrolling through PDFs. Stock Titan delivers real-time filing updates, context-rich charts, and expert analysis tailored to Genpact’s business-process management model—so you can focus on decisions, not document hunting.
Form 4 filing summary for L3Harris Technologies (LHX)
On 1 July 2025, non-employee director Joanna L. Geraghty acquired 168.81 phantom stock units of L3Harris through the company’s 2019 Non-Employee Director Compensation Plan. The units were credited in lieu of a portion of her quarterly cash retainer and are to be settled in L3Harris common stock when she leaves Board service. The reference share value used for the credit was $252.18 per unit.
Following the transaction, Geraghty’s total beneficial holding under the plan increased to 4,430.78 phantom stock units, which includes 13.03 units earned from dividend equivalents since her last report. All holdings are listed as direct and there were no derivative securities involved.
The filing reflects routine director compensation deferral rather than an open-market purchase; therefore, the transaction is unlikely to be materially significant to L3Harris’s share-count or governance profile.
Form 4 overview: Director Laura Berner of Bolt Biotherapeutics (BOLT) reported a single equity-based transaction dated May 27 2025. She received a non-qualified stock option for 1,100 common shares at an exercise price of $6.40 per share. All figures give effect to the 1-for-20 reverse stock split that the company executed on June 6 2025.
Key terms of the grant:
- Vesting: Options vest on the earlier of May 27 2026 or the day immediately prior to the next annual meeting, subject to continued service.
- Change-in-control: The award vests in full upon a change-in-control event.
- Expiration: May 26 2035 (10-year life).
No shares were purchased or sold; the filing reflects compensation-related option issuance. Post-grant, Berner beneficially owns 1,100 derivative securities and no disclosed non-derivative common shares.
Corporate context: The recent reverse split consolidated each 20 common shares into one, reducing the share count and proportionally increasing exercise prices. Prior to the split, the grant was for 22,000 shares at $0.32 per share. The filing provides no additional financial or operational data.
Genpact Limited (NYSE: G) filed an 8-K reporting the appointment of John Hinshaw to its Board of Directors, effective July 1 2025. Hinshaw, 54, brings extensive operations and technology leadership experience from prior senior roles at HSBC (Group COO, 2020-2024), Hewlett-Packard/HPE (EVP Technology & Operations, 2011-2016), Boeing (CIO & GM, 2007-2011) and Verizon (SVP & CIO, Wireless Division). He currently serves as an independent director at Sysco and has held board seats at BNY Mellon and DocuSign.
Under Genpact’s non-employee director compensation program, Hinshaw will receive an annual cash retainer of $70,000 and restricted share units (RSUs) worth $210,000. Because his service begins mid-year, 2025 compensation will be pro-rated to $35,000 cash plus RSUs worth $105,000, valued at the closing share price on the grant date. He also executed the company’s standard director indemnification agreement.
The filing contains no other operational, financial or strategic disclosures.
FAQ
What is the current stock price of Genpact (G)?
What is the market cap of Genpact (G)?
What core services does Genpact offer?
How does Genpact generate business impact?
What industries does Genpact serve?
How is Genpact positioned within the competitive landscape?
What role does technology play in Genpact's business model?
How does Genpact support digital transformation for its clients?
What is the significance of Genpact's heritage as a GE spin-off?
How does Genpact ensure its solutions remain effective over time?
